The Use of Non-Human Primates in Biological and Medical Research: Evidence Submitted by FRAME to the Academy of Medical Sciences/Medical Research Council/Royal Society/Wellcome Trust Working Group
Restricted accessOtherFirst published online October, 2005
The Use of Non-Human Primates in Biological and Medical Research: Evidence Submitted by FRAME to the Academy of Medical Sciences/Medical Research Council/Royal Society/Wellcome Trust Working Group
The Academy of Medical Sciences, the Medical Research Council, the Royal Society and the Wellcome Trust are undertaking a study into the use of non-human primates in biological and medical research. An independent working group of scientific experts, led by Sir David Weatherall, aims to produce a report summarising the findings of this study, early in 2006. The trends in primate research, and the nature and effects of recent and proposed changes in the global use of non-human primates in research, will be investigated. The associated ethical, welfare and regulatory issues, and the role and impact of the Three Rs principles of refinement, reduction and replacement will also be reviewed. As part of this study, a call for evidence was made. The evidence submitted by FRAME emphasised that the use of non-human primates for fundamental research or for regulatory testing still fails to take into account the fact that, although non-human primates are anatomically and physiologically similar to humans, they are not necessarily relevant models for studies on human disease or human physiology. FRAME continues to believe that we have a duty to ensure that these animals are not used without overwhelming evidence that they are the only suitable and relevant models for use in work of undeniable significance.
CarlssonH.E., SchapiroS.J., FarahI., & HauJ. (2004). Use of primates in research: a global overview. American Journal of Primatology63, 225–237.
2.
HagelinJ. (2005). The use of live apes in research in the twenty-first century. ATLA33, 111–118.
3.
CEC (2005). Report from the Commission to the Council and the European Parliament: Fourth Report on the Statistics on the Number of Animals Used for Experimental and Other Scientific Purposes in the Member States of the European Union. COM(2005) 7 final, 20 January 2005. 13 pp. Brussels, Belgium: European Commission.
4.
BallsM. (1995). The use of non-human primates as laboratory animals in Europe: moving toward the zero option. ATLA23, 284–286.
CaceresM., LachuerJ., ZapalaM.A., RedmondJ.C., KudoL., GeschwindD.H., LockhartD.J., PreussT.M., & BarlowC. (2003). Elevated gene expression levels distinguish human from nonhuman primate brains. Proceedings of the National Academy of Sciences USA100, 13030–13035.
7.
UddinM., WildmanD.E., LiuG.Z., XuW.B., JohnsonR.M., HofP.R., KapatosG., GrossmanL.I., & GoodmanM. (2004). Sister grouping of chimpanzees and humans as revealed by genome-wide phylogenetic analysis of brain gene expression profiles. Proceedings of the National Academy of Sciences USA101, 2957–2962.
8.
BuxhoevedenD., & CasanovaM. (2000). Comparative lateralisation patterns in the language area of human, chimpanzee, and rhesus monkey brains. Laterality5, 315–330.
9.
GiladY., WiebeV., PrzeworskiM., LancetD., & PääboS. (2003). Loss of olfactory receptor genes coincides with the acquisition of full trichromatic vision in primates. Plos Biol2e5, DOI 10.1371/journal.pbiol.0020005 (Accessed 09.09.05).
10.
DennisJ.C., SmithT.D., BhatnagarK.P., BonarC.J., BurrowsA.M., & MorrisonE.E. (2004). Expression of neuron-specific markers by the vomeronasal neuroepithelium in six species of primates. Anatomical Record Part A — Discoveries in Molecular, Cellular and Evolutionary Biology281A, 1190–1200.
11.
ReynoldsP.D., PittlerS.J., & ScammellJ.G. (1997). Cloning and expression of the glucocorticoid receptor from the squirrel monkey (Saimiri boliviensis boliviensis), a glucocorticoid-resistant primate. Journal of Clinical Endocrinology and Metabolism82, 465–472.
12.
AbbottD.H., FoongSC, BarnettDK, & DumesicDA. (2004). Nonhuman primates contribute unique understanding to anovulatory infertility in women. ILAR Journal45, 116–131.
13.
PlattJ.L., & ParkerW. (1995). Another step towards xenotransplantationNature Medicine1, 1248–50.
14.
SandrinM.S., FodorW.L., MouhtourisE., OsmanN., CohneyS., RollinsS.A., GuilemtteE.R., SetterE., SquintoS.P., & McKenzieI.F.C. (1995). Enzymatic remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nature Medicine1, 1261–7.
15.
Anon. (1996). Animal-to-Human Transplants. The Ethics of Xenotransplantation.168 pp. London, UK: Nuffield Council on Bioethics.
16.
ChanW.S., ChongK.Y., MartinovichC., SimerlyC., & SchattenG. (2001). Transgenic monkeys produced by retroviral gene transfer into mature oocytes. Science, New York291, 309–312.
17.
MephamT.B., CombesR.D., BallsM., BarbieriO., BlokhuisH.J., CostaP., CrillyR.E., de Cock BuningT., DelpireV.C., O'HareM.J., HoudebineL.-M., van KreijlC.F., van der MeerM., ReinhardtC.A., WolfE., & van ZellerA.-M. (1998). The report and recommendations of ECVAM Workshop 28: The use of transgenic animals in the European Union. ATLA26, 21–43.
18.
Anon. (2002). The Welfare of Non-human Primates used in Research.135 pp. Brussels, Belgium: European Commission.
19.
MontagnonB.J., & Vincent-FalquetJ.C. (1998). Experience with the Vero cell line. Developments in Biological Standardization93, 119–123.
RezapkinG.V., AlexanderW., DragunskyE., ParkerM., PomeroyK., AsherD.M., & ChumakovK.M. (1998). Genetic stability of Sabin 1 strain of poliovirus: implications for quality control of oral poliovirus vaccine. Virology245, 183–187.
22.
RezapkinG.V., FanL.J., AsherD.M., FibiM.R., DragunskyE.M., & ChumakovK.M. (1999). Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype. Virology258, 152–160.
23.
Anon. (2000). Vaccines and biomedicines. WHO Drug Information14, 216.
24.
DragunskyE., NomuraT., KarpinskiK., FureszJ., WoodD.J., PerivikovY., AbeS., KurataT., VanloockeO., KarganovaG., TaffsR., HeathA., IvshinaA., & LevenbookI. (2003). Transgenic mice as an alternative to monkeys for neurovirulence testing of live oral poliovirus vaccine: validation by a WHO collaborative study. Bulletin of the World Health Organisation81, 251–262.
ter MeulenJ., BakkerA.B.H., van den BrinkE.N., WeverlingG.J., MartinaB.E.E., HaagmansB.L., KuikenT., de KruifJ., PreiserW., SpaanW., GelderblomH.R., GoudsmitJ., & OsterhausA.D.M.E. (2004). Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. The Lancet363, 2139–2141.
30.
CzubM., WeingartlH., CzubS., HeR.T., & CaoJ.X. (2005). Evaluation of modified vaccine virus Ankara based recombinant SARS vaccine in ferrets. Vaccine23, 2273–2279.
31.
NathB.M., SchumannK.E., & BoyerJ.D. (2000). The chimpanzee and other non-human-primate models in hIV-1 vaccine research. Trends in Microbiology8, 426–431.
BendeS., & JohnstonM.I. (2000). Update: Search for an AIDS vaccine. AIDS Reader10, 526–538.
34.
NabelG.J. (2001). Challenges and opportunities for development of an AIDS vaccine. Nature Medicine410, 1002–1007.
35.
LangleyG. (2002). Phasing Out Primate Use in Belgian Laboratories.85 pp. Brussels, Belgium: GAIA.
36.
PetersB.S. (2000). HIV immunotherapeutic vaccines. Antiviral Chemistry and Chemotherapy11, 311–320.
37.
ZhengL., HuangX.L., FanZ., BorowskiL., WilsonC.C., & RinaldoC.R. (1999). Delivery of liposome encapsulated HIV type 1 proteins to human dendritic cells for stimulation of HIV type 1- specific memory of cytotoxic T lymphocyte responses. AIDS Research and Human Retroviruses15, 1011–1020.
38.
CollinsK.B., PattersonB.K., NausG.J., LandersD.V., & GuptaP. (2000). Development of a new in vitro organ culture model to study transmission of HIV-1 in the female genital tract. Nature Medicine6, 475–479.
39.
KawamuraT., CohenC.C., BorrisD.L., AquilinoE.A., GlushakovaS., MargolisL.B., OrensteinJ.M., OffordR.E., NeurathA.R., & BlauveltA. (2000). Candidate microbiocides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. Journal of Experimental Medicine192, 1491–1500.
40.
SchwartzD.H., & IyengarS. (2001). Positron emission tomography of the immune response to infection and vaccination. Alternatives Today (Spring), 10–12.
41.
Anon. (2004). Seventh Report of The Animal Welfare Advisory Committee.11 pp. Sevenoaks, Kent, UK: dstl.
42.
GeisbertT.W., YoungH.A., JahrlingP.B., DavisK.J., LarsenT., KaganE., & HensleyL.E. (2003). Pathogenesis of Ebola hemorrhagic fever in primate models — Evidence that haemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. American Journal of Pathology163, 2371–2382.
43.
GeisbertT.W., HensleyL.E., JahrlingP.B., LarsenT., GeisbertJ.B., ParagasJ., YoungH.A., FredekingT.M., RoteW.E., & VlasukG.P. (2003). Treatment of Ebola virus infection with a recombinant inhibitor of factor Vila/tissue factor: a study in rhesus monkeys. The Lancet362, 1953–1958.
44.
PhippsA.J., PremanandanC., BarnewallR.E., & LairmoreM.D. (2004). Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines. Microbiology and Molecular Biology Reviews68, 617–629.
45.
MonathT.P., CaldwellJ.R., MundtW., FuscoJ., JohnsonC.S., BullerM., JianL., GardnerB., DowningG., BlumP.S., KempT., NicholsR., & WeltzinR. (2004). ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) — a second-generation smallpox vaccine for biological defence. International Journal of Infectious Diseases8, Suppl. 2, S31–S44.
46.
JahrlingP.B., HensleyL.E., MartinezM.J., LeDucJ.W., RubinsK.H., RelmanD.A., & HugginsJ.W. (2004). Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proceedings of the National Academy of Sciences USA101, 15196–15200.
47.
Anon. (2005). The Ethics of Research Involving Animals.335 pp. London, UK: Nuffield Council on Bioethics.
48.
SmithJ.A., & BoydK.M. (eds.). (2002). The Use of Non-Human Primates in Research and Testing.61 pp. Leicester, UK: British Psychological Society.
49.
Anon. (2002). The Use of Primates Under the Animals (Scientific Procedures) Act (1986): Analysis of Current Trends with Particular Reference to Regulatory Toxicology.39 pp. London, UK: Home Office Animal Procedures Committee.
50.
FRAME/CRAE. (1987). The Use of Non-human Primates as Laboratory Animals in Great Britain.16 pp. Nottingham, UK: FRAME.
51.
BallsM. (2000). Proponent's statement: Moving toward the zero option for the use of non-human primates as laboratory animals. In Progress in the Reduction, Refinement and Replacement of Animal Experimentation (Ed. BallsM., van ZellerA.-M., & HalderM.), pp. 1587–1601. Amsterdam, The Netherlands: Elsevier Science B.V.
52.
BhogalN., GrindonC., CombesR., & BallsM. (2005). Toxicity testing: creating a revolution based on new technologies. Trends in Biotechnology23, 299–307.
LiW-H., & SaundersM.A. (2005). The chimpanzee and us. Nature, London437, 50–51.
55.
HillR.S., & WalshC.A. (2005). Molecular insights into human brain evolution. Nature, London437, 64–67.
56.
The Chimpanzee Sequencing and Analysis Consortium (2005). Initial sequence of the chimpanzee genome and comparison with the human genome. Nature, London437, 69–87.
57.
VandebergJ.L., & ZolaS.M. (2005). A unique biomedical resource at risk. Nature, London437, 30–32.
